Women exposed in utero to Diethylstilbestrol (DES) should have an initial colposcopic examination. In the absence of an abnormality at that first examination, only routine cervical screening is required. Women whose initial examination showed an abnormality or stigmata of DES exposure may require annual colposcopic examination of the vagina and cervix, in specialist centres, possibly for life. However, this should be considered on an individual basis by the woman concerned and her gynaecologist.
Royal College of Obstetricians and Gynaecologists:
Statement on fetal and maternal risks of diethylstilbestrol exposure in pregnancy (PDF 100Kb).
- NHSCSP home page
- Programme publications
- About cervical screening
- More information about the
screening programme- Information about cervical cancer
- Diethylstilbestrol (DES) exposed women
- Liquid Based Cytology (LBC)
- LBC implementation guidance
- Who does what in the programme
- Quality Assurance and Training
- Section 60 of the Health and Social Care Act 2001
- Cervical cytology training centres
- Human Papilloma virus (HPV)
- HPV Sentinel Sites implementation project
- HMR101 Request/Report Form
- Cytology improvement guide - 14 day turnaround time
- Research in cervical screening
- Frequently asked questions
- Programme statistics
- Programme news index
- Useful links